496 related articles for article (PubMed ID: 26400911)
1. Broadly neutralizing human monoclonal JC polyomavirus VP1-specific antibodies as candidate therapeutics for progressive multifocal leukoencephalopathy.
Jelcic I; Combaluzier B; Jelcic I; Faigle W; Senn L; Reinhart BJ; Ströh L; Nitsch RM; Stehle T; Sospedra M; Grimm J; Martin R
Sci Transl Med; 2015 Sep; 7(306):306ra150. PubMed ID: 26400911
[TBL] [Abstract][Full Text] [Related]
2. Cloning of the first human anti-JCPyV/VP1 neutralizing monoclonal antibody: epitope definition and implications in risk stratification of patients under natalizumab therapy.
Diotti RA; Mancini N; Clementi N; Sautto G; Moreno GJ; Criscuolo E; Cappelletti F; Man P; Forest E; Remy L; Giannecchini S; Clementi M; Burioni R
Antiviral Res; 2014 Aug; 108():94-103. PubMed ID: 24909571
[TBL] [Abstract][Full Text] [Related]
3. Synthetic antibodies and peptides recognizing progressive multifocal leukoencephalopathy-specific point mutations in polyomavirus JC capsid viral protein 1.
Chen G; Gorelik L; Simon KJ; Pavlenco A; Cheung A; Brickelmaier M; Chen LL; Jin P; Weinreb PH; Sidhu SS
MAbs; 2015; 7(4):681-92. PubMed ID: 25879139
[TBL] [Abstract][Full Text] [Related]
4. Divergent Trends of Anti-JCPyV Serum Reactivity and Neutralizing Activity in Multiple Sclerosis (MS) Patients during Treatment with Natalizumab.
Diotti RA; Capra R; Moiola L; Caputo V; De Rossi N; Sangalli F; Martinelli V; Burioni R; Clementi M; Mancini N
Viruses; 2016 May; 8(5):. PubMed ID: 27164128
[TBL] [Abstract][Full Text] [Related]
5. Progressive multifocal leukoencephalopathy-associated mutations in the JC polyomavirus capsid disrupt lactoseries tetrasaccharide c binding.
Maginnis MS; Ströh LJ; Gee GV; O'Hara BA; Derdowski A; Stehle T; Atwood WJ
mBio; 2013 Jun; 4(3):e00247-13. PubMed ID: 23760462
[TBL] [Abstract][Full Text] [Related]
6. Prevention and therapy of JC polyomavirus-mediated progressive multifocal leukoencephalopathy - a realistic possibility?
Jelcic I; Combaluzier B; Jelcic I; Sospedra M; Grimm J; Martin R
Swiss Med Wkly; 2017; 147():w14520. PubMed ID: 29120025
[TBL] [Abstract][Full Text] [Related]
7. The human JC polyomavirus (JCPyV): virological background and clinical implications.
Hirsch HH; Kardas P; Kranz D; Leboeuf C
APMIS; 2013 Aug; 121(8):685-727. PubMed ID: 23781977
[TBL] [Abstract][Full Text] [Related]
8. Serum IgG antibodies from healthy subjects up to 100 years old react to JC polyomavirus.
Bononi I; Mazzoni E; Pietrobon S; Manfrini M; Torreggiani E; Rossini M; Lotito F; Guerra G; Rizzo P; Martini F; Tognon M
J Cell Physiol; 2018 Aug; 233(8):5513-5522. PubMed ID: 29323725
[TBL] [Abstract][Full Text] [Related]
9. Which is the best PML risk stratification strategy in natalizumab-treated patients affected by multiple sclerosis?
Prezioso C; Zingaropoli MA; Iannetta M; Rodio DM; Altieri M; Conte A; Vullo V; Ciardi MR; Palamara AT; Pietropaolo V
Mult Scler Relat Disord; 2020 Jun; 41():102008. PubMed ID: 32087593
[TBL] [Abstract][Full Text] [Related]
10. ERK Is a Critical Regulator of JC Polyomavirus Infection.
DuShane JK; Wilczek MP; Mayberry CL; Maginnis MS
J Virol; 2018 Apr; 92(7):. PubMed ID: 29321332
[TBL] [Abstract][Full Text] [Related]
11. JCPyV VP1 Mutations in Progressive MultifocalLeukoencephalopathy: Altering Tropismor Mediating Immune Evasion?
Lauver MD; Lukacher AE
Viruses; 2020 Oct; 12(10):. PubMed ID: 33053912
[TBL] [Abstract][Full Text] [Related]
12. JC polyomavirus (JCV) and monoclonal antibodies: friends or potential foes?
Diotti RA; Nakanishi A; Clementi N; Mancini N; Criscuolo E; Solforosi L; Clementi M
Clin Dev Immunol; 2013; 2013():967581. PubMed ID: 23878587
[TBL] [Abstract][Full Text] [Related]
13. Comparison of qPCR with ddPCR for the Quantification of JC Polyomavirus in CSF from Patients with Progressive Multifocal Leukoencephalopathy.
Ngouth N; Monaco MC; Walker L; Corey S; Ikpeama I; Fahle G; Cortese I; Das S; Jacobson S
Viruses; 2022 Jun; 14(6):. PubMed ID: 35746716
[TBL] [Abstract][Full Text] [Related]
14. New sequence polymorphisms in the outer loops of the JC polyomavirus major capsid protein (VP1) possibly associated with progressive multifocal leukoencephalopathy.
Zheng HY; Takasaka T; Noda K; Kanazawa A; Mori H; Kabuki T; Joh K; Oh-Ishi T; Ikegaya H; Nagashima K; Hall WW; Kitamura T; Yogo Y
J Gen Virol; 2005 Jul; 86(Pt 7):2035-2045. PubMed ID: 15958683
[TBL] [Abstract][Full Text] [Related]
15. Progressive multifocal leukoencephalopathy.
Weissert R
J Neuroimmunol; 2011 Feb; 231(1-2):73-7. PubMed ID: 20937530
[TBL] [Abstract][Full Text] [Related]
16. Central role of JC virus-specific CD4+ lymphocytes in progressive multi-focal leucoencephalopathy-immune reconstitution inflammatory syndrome.
Aly L; Yousef S; Schippling S; Jelcic I; Breiden P; Matschke J; Schulz R; Bofill-Mas S; Jones L; Demina V; Linnebank M; Ogg G; Girones R; Weber T; Sospedra M; Martin R
Brain; 2011 Sep; 134(Pt 9):2687-702. PubMed ID: 21908874
[TBL] [Abstract][Full Text] [Related]
17. The effect of plasma exchange on serum anti-JC virus antibodies.
Subramanyam M; Plavina T; Khatri BO; Fox RJ; Goelz SE
Mult Scler; 2013 Jun; 19(7):912-9. PubMed ID: 23232602
[TBL] [Abstract][Full Text] [Related]
18. A Difficult Decision: Atypical JC Polyomavirus Encephalopathy in a Kidney Transplant Recipient.
Bialasiewicz S; Hart G; Oliver K; Agnihotri SP; Koralnik IJ; Viscidi R; Nissen MD; Sloots TP; Burke MT; Isbel NM; Burke J
Transplantation; 2017 Jun; 101(6):1461-1467. PubMed ID: 27367472
[TBL] [Abstract][Full Text] [Related]
19. Human iPS cell-derived astrocytes support efficient replication of progressive multifocal leukoencephalopathy-type JC polyomavirus.
Shimbo E; Nukuzuma S; Tagawa YI
Biochem Biophys Res Commun; 2020 Dec; 533(4):983-987. PubMed ID: 33008586
[TBL] [Abstract][Full Text] [Related]
20. BK virus capsid antibodies are associated with protection against subsequent development of PML in HIV-infected patients.
Rossi F; Li X; Jacobson L; Levine AJ; Chen Y; Palella FJ; Margolick J; Viscidi R
Virology; 2015 Nov; 485():467-72. PubMed ID: 26356797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
